FDA clears Scancell's application for phase three trial
26th Jan 2026 14:10
(Sharecast News) - Scancell said on Monday that the US Food and Drug Administration had cleared its investigational new drug application for a registrational phase three trial of its 'iSCIB1+ Immunobody' in advanced melanoma, paving the way for a global late-stage study planned to begin in 2026.
Read moreScancell reports further data from DNA cancer immunotherapy trial
9th Dec 2025 13:53
(Sharecast News) - Scancell reported further positive clinical data for its DNA cancer immunotherapy iSCIB1+, on Tuesday, saying updated phase two results supported its selection for late-stage development in first-line advanced melanoma and reinforce the target patient population.
Read moreScancell reports strong results from Immunobody trial
7th Nov 2025 12:54
(Sharecast News) - Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing significant improvements in progression-free survival for patients with late-stage melanoma.
Read moreScancell narrows loss as it progresses immunotherapy pipeline
11th Sep 2025 14:30
(Sharecast News) - Scancell reported progress across its immunotherapy pipeline on Thursday, as it narrowed annual losses and prepared for late-stage development of its lead melanoma treatment.
Read moreScancell starts dosing next cohort in melanoma treatment study
25th Jun 2025 12:56
(Sharecast News) - Scancell announced on Wednesday that it has started dosing patients in cohort four of its phase 2 'SCOPE' clinical trial, evaluating the intradermal administration and accelerated dosing of its iSCIB1+ immunotherapy for advanced unresectable melanoma.
Read moreScancell shares jump on new antibody agreement with major biotech firm
12th Jun 2024 07:53
(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".
Read moreScancell appoints healthcare finance veteran as new CFO
29th Aug 2023 14:27
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
Read moreScancell to present positive recent findings at oncology summit
2nd Jun 2023 13:18
(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago from 2 to 6 June.
Read moreScancell shares jump on positive cancer vaccine progress
21st Feb 2023 12:14
(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.
Read moreScancell licenses Vaccitech IP for its next vaccine candidate
7th Nov 2022 09:29
(Sharecast News) - Scancell has in-licensed 'SNAPvax' technology from clinical-stage biopharmaceutical company Vaccitech, it announced on Monday.
Read moreScancell enrols and doses first patient in latest cancer trial
31st Oct 2022 16:46
(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.
Read moreScancell losses widen on expense of ongoing trials
28th Oct 2022 14:42
(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.
Read moreScancell inks licensing deal with Nasdaq-traded Genmab
25th Oct 2022 14:34
(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.
Read moreScancell presents new, positive data on possible cancer therapies
23rd Sep 2022 13:31
(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.
Read moreScancell developing 'promising' new cancer treatment approach
23rd Jun 2022 12:38
(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.
Read more